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Abstract
Background: The International Association for Study of Lung Cancer Staging Committee proposes for the next revision of TNM (tumour, nodes,
metastases) classification that additional nodules in a different lobe of the ipsilateral lung moves from an M1 designation to T4, while additional
nodule(s) in the contralateral lung should be classified as M1a, because of poorer survival. We analysed the survival after surgery of patients
presenting with synchronous lung cancers located in a different lobe or lung.Methods: A database of 1551 patients operated on for non-small-cell
lung cancer (NSCLC) between 1990 and 2007 was evaluated for unilateral (other lobe) (n = 15) and bilateral (n = 28) synchronous multiple lung
cancers. The relationships among the location of tumours, histology, date of surgery (before and after 2000), lymph node metastasis, type of
surgery, adjuvant therapy and survival were analysed.Results: The 5-year survival for all synchronousmultiple lung cancers (n = 43) was 34%, with
a median survival of 32 months. Postoperative mortality was 7%. On univariate analysis, only lymph node metastasis and surgery before the year
2000 affected the overall survival adversely, and both prognostic factors maintained a statistical significance on multivariate analysis. The 5-year
survivals were 57% and 0% for patients without (n = 25) and with (n = 18) lymph node metastasis, respectively ( p = 0.004), and were 43% and 18%
for patients operated upon after (n = 27) and before (n = 16) the year 2000, respectively ( p = 0.01), perhaps reflecting a better selection process
related to the extensive use of positron emission tomography (PET) scanning. The 5-year survival was not different between bilateral (43%) and
unilateral (27%) synchronous lung cancers (p = n.s.). Conclusions: Our data support complete surgical resection of synchronous multiple lung
cancers in patients with node-negative NSCLC. Even patients with bilateral lung cancer should not be treated as metastatic disease. Provided
there is no evidence of node and distant metastasis, after an extensive preoperative work-up, including PET scanning and mediastinoscopy,
bilateral surgical resection should be performed in fit patients.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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European Journal of Cardio-thoracic Surgery 37 (2010) 1198—12041. Background
With the recent advancement in diagnostic imaging
techniques, such as multi-slice spiral computed tomography
(CT) and positron emission tomography-computed tomogra-
phy (PET-CT) scan, thoracic surgeons are increasingly facing
the problem of synchronous multiple lung nodules, which can
correspond to multiple primary lung cancers (MPLCs), or
pulmonary metastasis from the index tumour.
This distinction can have important clinical and ther-
apeutic implications, but the preoperative diagnosis is
almost impossible and can remain difficult even after
pathologic examination of the resected specimen, consider-
ing that an identical histology does not exclude two primaries§ Presented at the 17th European Conference on General Thoracic Surgery,
Krakow, Poland, May 31—June 3, 2009.
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widely adopted tool to achieve a diagnosis, but its
preoperative usefulness is impaired by the difficulty to
obtain adequate specimens from all foci of tumours.
According to the last TNM (tumour, nodes, metastases)
classification, revised in 1997, the presence of multiple
tumour nodules located in a different lobe or lung is classified
as M1 (stage IV) [2]; consequently, most patients are treated
with chemotherapy or chemo/radiotherapy and are not
offered surgical resection.
For instance, the proposal from the International
Association for Study of Lung Cancer Staging Committee
(IASLC) for the next upcoming revision of the TNM staging
system to reclassify an additional nodule in the contralateral
lung as M1a is based on data of 362 patients with synchronous
bilateral lung cancer, of which only seven underwent
bilateral surgery [3].
However, few selected patients with synchronous multiple
lung cancer (MLC) can benefit from surgery [4—8], but theurgery. Published by Elsevier B.V. All rights reserved.
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selection for surgery controversial.
It must be also emphasised that majority (57—86%) of the
additional nodules seen radiographically in patients with
clinical stage I—III NSCLC are benign lesions [9,10]. There-
fore, a patient should not be denied a curative approach on
the basis of a second pulmonary nodule without a definitive
tissue diagnosis.
The additional nodules are often small and the only way to
obtain tissue from the lesion is by thoracotomy, meaning that
a decision has to be established on the basis of clinical
criteria such as radiological characteristics.
Our policy has always consisted in offering the chance of
surgery to patients with synchronous MLC if judged
completely resectable and in absence of extrathoracic
metastasis.
We reviewed our experience with synchronous MLCs
discovered before surgery in order (1) to estimate the
outcome after surgical resection and (2) to determine the
clinical and pathological prognostic factors of long-term
survival to improve our selection process of candidates to
aggressive surgical treatment.
2. Matherials and methods
The lung cancer database of the Thoracic Surgery Unit at
the University of Siena was reviewed to identify all patients
operated on for non-small-cell lung cancer (NSCLC) from
1990 to 2007.
Patients with more than one physically distinct tumour,
located in a different lobe or lung and discovered
preoperatively, were selected and form the basis of the
study.
These tumours were defined as MLCs irrespective of
histology (same or different), location (different lobe or
lung) and in the absence of extrathoracic disease.
All the patients with synchronous lesions within the same
lobe as the primary tumour had been excluded from this
study, since they are often discovered during or after surgery
and no extra work-up nor a different surgical approach is
required.
Patients with carcinoid tumours and bronchioloalveolar
adenocarcinomas (BACs) showing pure ground-glass opacity
at CT scan were excluded as well.
Assessment included history, physical examination, rou-
tine blood tests, electrocardiogram, echocardiography,
blood gas analysis, spirometry and estimation of CO diffusion
capacity of the lung.
Cardiac stress tests and coronary angiography were
performed when indicated by history of angina pectoris or
by significant ischaemic signs in the basal electrocardiogram;
cardiorespiratory tests and/or lung perfusion scintigraphy
were executed as second-level tests in case of predicted
postoperative forced expiratory volume in 1 s (FEV1) lesser
than 40%.
Clinical staging was based on broncoscopy, contrast-
enhanced CTof the chest, upper abdomen and brain, as well
as bone scintigraphy; mediastinoscopy was carried out
selectively in case of enlarged mediastinal lymph nodes on
CT (short axis >1 cm).rom https://academic.oup.com/ejcts/article-abstract/37/5/1198/600918
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synchronous MLCs.
For bilateral lesions, our surgical policy favoured sequen-
tial lobectomies over sublobar resections if respiratory
function allowed it, while in case of unilateral resection,
whenever possible, we tried to perform lobectomy and
wedge resection, avoiding pneumonectomy.
In case of anatomical resection (lobar resection, i.e.,
lobectomy, bilobectomy and pneumonectomy), a systematic
mediastinal nodal dissection was performed.
Sublobar resections (e.g., segmentectomy and wedge
resection) and lymph node sampling were preferred for small
peripheral tumours (<2 cm) in patients with limited
pulmonary function tests, especially after the first operation.
The second surgery was performed only when the patient
had fully recovered, as demonstrated by a fresh spirometry
and in the absence of progressive disease at re-staging with
CT of the chest, brain and upper abdomen.
Tumour histology was classified according to the World
Health Organization classification [11]; pathologic staging
was based on the International System for Staging Lung
Cancer [12].
The standard follow-up protocol included a total-body CT
scan and serum markers every 6 months for the first 2 years,
then a chest CT scan every 12 months until the 5th year.
Follow-up information was obtained either during office visits
or by telephone with patients, their relatives or physician,
and follow-up was completed in all patients through January
2009.
Quantitative variables were expressed as mean  stan-
standard deviation; range is reported where appropriate.
Survival was defined as the interval between the date of
surgery and date of death or last follow-up, whereas disease-
free survival was defined as the duration from pulmonary
resection to the date of recurrence or non-cancer-related
death.
The survival curves were computed according to the
Kaplan—Meyer method and the differences between groups
were determined by long-rank test.
A series of covariates were tested for their influence upon
overall survival, including sex, age, location of tumours,
presence of co-morbidity, date of surgery (before and after
2000), lymph node metastasis, adjuvant therapy and type of
surgery (lobar vs sublobar).
Identification of the independent impact of covariates
on long-term survival was made through Cox regression
analysis.
The Fisher’s exact and K2 tests were used to estimate the
differences between synchronous MLC categories on clinical
and pathological variables previously described. All statis-
tical tests were two-sided: a p-value less or equal to 0.05 was
accepted for statistical significance.
Perioperative mortality (defined as death occurring intra-
operatively or in-hospital or within 30 days after operation)
was included in calculation of survival.
The Statistical Package for the Social Sciences version
14.0 software (SPSS Inc., Chicago, IL, USA) was used for all
analysis.
The University Hospital of Siena Ethic Board granted
approval for this study, with no requirement for patient’s
consent considering that this was a retrospective study.
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Table 2
Details of surgical procedures performed (percentages reported within col-
umns).
Unilateral MPLC (n = 15) Bilateral MPLC (n = 28)
Lobectomy and sublobar
resection
8 (53.3) Bilateral sublobar
resection
2 (7.1)
Sublobar resection 2 (13.3) Lobectomy and sublobar
resection
13 (46.4)
Bilobectomy 2 (13.3) Bilateral lobectomy 10 (35.7)
Pneumonectomy 3 (20) Pneumonectomy and
sublobar resection
3 (10.7)
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During the study period (1990—2007), 50 patients were
found to have unilateral (other lobe) (n = 15) or bilateral
(n = 35) synchronous MLCs, representing 3.2% of all pulmon-
ary resections (n = 1551) for NSCLC at the University of Siena.
We could surgically treat only one side of seven patients
with bilateral lesions: the insufficient pulmonary reserve of
three patients after the first resection prevented the
contralateral resection. These patients were treated with
radiotherapy.
Two patients in whom the first resection was incomplete
and two other patients with a progressive disease on re-
staging were treated with chemotherapy.
Those 28 patients with bilateral disease who underwent
surgery on both sides and those 15 patients with unilateral
MLCs were further analysed.
The main features of these 43 patients are listed in
Table 1. Forty males and three females with the mean age of
66 (6.9) years (range: 44—77 years) are enumerated in the
list.
A total of 40 patients (93%) were smokers, and 18 patients
(42%) were current smokers at the time of surgery.
Co-morbidity, mainly cardiopulmonary, was present in 14
patients (32%).
Five patients (12%) had a previous malignancy, with no
evidence of active disease at the time of evaluation for their
new primary lung tumour.
Two malignant tumours had been found in 37 patients
while the remaining six (14%) had three or more.
Since 2000, all patients (n = 27; 60%) had PET scan,
including 20 patients in the bilateral group and seven
patients in the unilateral group. Fourteen patients (32%)
underwent mediastinoscopy. All the 28 patients with
bilateral lesions were treated sequentially, with a median
interval of 67 days (range: 35—300 days).Table 1
Main features of population (percentages reported within columns).
Unilateral nodules
in non-primary
lobe (n = 15)
Contralateral
additional
nodules (n = 28)
Total
(n = 43)
p
Age (mean  SD) 66.9  7.6 66.5  6.7 66.7  6.9 0.86
Sex
Male 13 (86.7) 27 (96.4) 40 (93)
Female 2 (13.3) 1 (3.6) 3 (7)
Smokers 0.265
Yes 15 (100) 25 (89.3) 40 (93)
No 0 3 (10.7) 3 (7)
Co-morbidity 0.048
Yes 2 (13.3) 12 (42.9) 14 (32.6)
No 13 (86.7) 16 (57.1) 29 (67.4)
cTNM 0.145
100 1 (7.7) 7 (25) 8 (18.6)
200 13 (86.6) 12 (42.9) 25 (58.1)
210 1 (7.7) 2 (7.1) 3 (7)
300 0 1 (3.6) 1 (2.3)
400 0 5 (17.9) 5 (11.6)
410 0 1 (3.5)) 1 (2.3)
Period 0.103
1990—1999 8 (53.3) 8 (28.6) 16 (37.2)
2000—2007 7 (46.7) 20 (71.4) 27 (62.8)
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Thirty-one lesions were resected by a sublobar resection in 28
patients (65%), including 12 segmentectomies and 19 wedge
resections. Systematic nodal dissection was performed in 23
patients (53%) and lymph node sampling in 20 (47%).
One or more complications developed in 16 patients,
giving an overall morbidity of 37%. The most frequent
complication was prolonged air leak, which was observed in
six cases, followed by supraventicular arrhythmia in two
cases; pulmonary oedema in two cases; and pneumonia,
haemothorax requiring re-thoracotomy, empyema and
atelectasis requiring bronchoscopy in one case.
The operative mortality was 7% (n = 3). Acute respiratory
distress syndrome (ARDS) was the cause of death in two
patients and pulmonary embolism in one. Mean hospitalisa-
tion stay was 16 days for both two interventions.
Histology (Table 3) was identical in 27 patients (60%):
adenocarcinoma and squamous cell carcinoma were the
predominant histologic types, 65% and 25%, respectively. Two
patients in the bilateral group had a bronchioloalveolar
carcinoma in only one side. None of patients, including those
with previous malignances, had metastases from extrapul-
monary tumours, as confirmed by immunostaining on
resected specimens.
At the final pathological examination, the highest pN
factor was pN0 in 18 patients, pN1 in seven and pN2 in three
patients in the bilateral group, and pN0 in seven patients,
pN1 in two and pN2 in six patients in the unilateral group.
Eighteen patients received adjuvant treatment, consist-
ing of chemotherapy in 14 cases, radiotherapy in two cases
and sequential or combined chemo-radiotherapy in two other
cases.
The intent-to-treat survival analysis of all 50 patients with
synchronous MLCs showed a 3-year and 5-year survival of 40%
and 31%, respectively, with a median survival of 30 months
(95% confidence interval (CI): 20.5—39.5).
In the group of 43 patients who underwent planned
resection of all lesions, median survival was 32 months (95%
CI: 21.1—42.9), with an overall 3- and 5-year survival of 41%
and 34% (Fig. 1).
Survival was not affected by age, sex, location (unilateral
vs bilateral), presence of co-morbidity, histology (same vs
different), type of surgery (lobar vs sublobar) and adminis-
tration of adjuvant therapy.
On univariate analysis, only lymph node metastasis and
surgery before the year 2000 significantly worsened survival,
and both factors maintained a statistical significance on
multivariate analysis (Tables 4 and 5).
L. Voltolini et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 1198—1204 1201
Fig. 1. Cumulative survival of population.
Fig. 2. Survival according to nodal status.
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(n = 25) and with (n = 18) lymph node metastasis, respec-
tively ( p = 0.004), and 43% and 18% for patients operated
upon after (n = 27) and before (n = 16) the year 2000,
respectively ( p = 0.01) (Figs. 2 and 3).
At the mean follow-up of 33.5 months (range: 0—116
months), 15 patients (35%) were still alive and 28 (65%) had
died.
The cause of late death was related to cancer in 23 of 25
patients. The first site of recurrence was local (defined as any
disease in the chest) in nine (39%) patients and systemic in 14
(61%). Disease-free survivals were 37% at 3 years and 27% at 5
years.
4. Discussion
The appropriate diagnosis and management of patients
with synchronous MLCs remain controversial. Difficulties
mainly consist in defining an additional focus of cancer in the
lung separated from the main tumour, which may represent a
haematogenous metastasis, a lymphatic spread metastasis or
a second primary lung cancer. While an additional focus of
tumour in the same lobe does not change the treatment and
prognosis substantially, it is arduous to know how best to
treat patients with a second same histology cancer focus
located in a different lobe or lung. The American Joint
Committee on Cancer (AJCC) staging system classifies this
anatomical situation as M1, with the consequence that most
patients are not usually referred to surgery. However, the
highly variable frequency of synchronous tumours in surgical
series ranging from 0.8% to 21% [13—17] indicates that some
units probably have a more aggressive attitude to surgery, a
strategy that may be justified since complete resection offersTable 3
Histology (percentages reported within columns).
Unilateral (n = 15)
Same histology Adk—Adk 9 (60)
Epi—Epi 1 (6.7)
Different histology Epi—Adk 2 (13.3)
Epi—SCLC 1 (6.7)
Adk—SCLC 1 (6.7)
Epi—Adenosq 1 (6.7)
Abbreviations: Adk: adenocarcinoma, Epi: epidermoid carcinoma, Large C: large cell
lung carcinoma.
rom https://academic.oup.com/ejcts/article-abstract/37/5/1198/600918
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variable 5-year survival ranging from 0% to 70% for patients
with synchronous MLCs has been reported in the 1990s,
consistent with the difficulty of reliably classifying these
tumours [13—17].
In this study, the 5-year overall survival of the 43 patients
with MPLC who underwent resection of all lesions was 34%
with a median survival of 32 months.
Furthermore, the intent-to-treat survival analysis of all 50
patients showed a satisfactory 5-year survival of 31%.
Obviously, this is a highly selected group of patients and
we do not have information on patients with MLCs who were
not offered surgery to compare their survival.
We tried our best to reduce possible bias in interpreting
the results. We excluded important confounding variables,
such as carcinoid and pure BAC, because of their more
indolent biological behaviour. We also excluded patients with
same-lobe lesions who present a clear indication to surgery,
without requiring an extra work-up other than is required for
primary tumour or requiring a different surgical approach.
Alternatively, we included only patients whose lesions had
been discovered preoperatively, considering that lesions
detected during or after surgery are smaller and then
associated with a better prognosis.
Even after excluded these subcategories of patients, our
results in terms of survival rates are undoubtedly much
better than those reported for stage IV NSCLC [2] and show
that some selected patients with synchronous MLCs may
indeed benefit from an aggressive surgical attitude.
Our analysis demonstrates that lymph node involvement is
the strongest prognostic factor, as reported by other authors
[14,17—19]. In particular, Okada et al. found a 5-year survivalBilateral (n = 28) Total (n = 43)
Adk—Adk 13 (46.4) 27 (63)
Epi—Epi 4 (14.3)
Epi—Adk 6 (21.4) 16 (37)
Epi—Large C 2 (7.1)
Adk—Adenosq 1 (3.6)
Large C—Adk 1 (3.6)
Large C—Adenosq 1 (3.6)
anaplastic carcinoma, Adenosq: adeno-squamous carcinoma, SCLC: small-cell
L. Voltolini et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 1198—12041202
Table 4
Univariate analysis of predictors of survival.
Patients
(N)
Median
survival
(Months)
5-year
survival
(%)
p
Age
<67a 21 32 27.6 0.84
67a 22 27 36.6
Sex
Male 40 32 33.4 0.738
Female 3 23 50
Location 0.670
Ipsilateral 15 52 43
Bilateral 28 30 27
Histology 0.625
Same 27 36 34
Different 16 22 33
Type of resection 0.678
Sublobar 28 34 29
Lobar 15 32 42
Co-morbidity 0.387
Yes 14 26 26
No 29 34 37
Lymph node involvement 0.004
Yes (N1—N2) 18 23 0
No 25 71 57
Period 0.016
1990—1999 16 20 18
2000—2007 27 52 43
Italics: statistically significative.
a Median age of population.
Fig. 3. Survival according to period of surgery.
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involvement was a better predictor of survival than the
number and location of pulmonary metastasis [20]. Tung
et al. reported an excellent 5-year survival rate of 66.7% in
node-negative patients with ipsilateral multifocal NSCLC in
different lobes [21].
In our cohort of patients with synchronous MLCs, classified
as stage IV, we found a good 5-year survival of 57%, among the
node-negative patients, compared with 0% in node-positive
patients. These findings argue in favour of accurate
assessment of nodal status at the clinical evaluation. All
patients deserve PET scan and mediastinoscopy to exclude
from surgery patients with involvement of mediastinal lymph
nodes. The significant better survival found in patients with
bilateral MLCs operated on after 2000 (and staged with PET)Table 5
Multivariate analysis for survival (Cox regression).
Factor
Age <67a versus 67 years
Sex Male versus female
Smoke Yes versus no
Location Unilateral versus bilateral
Type of resection Sublobar versus lobar
Histology Same versus different
Adjuvant treatment No versus yes
Co-morbidity None versus 1 or more
N stage pN0 versus pN1—2
Period 1990—1999 versus 2000—2007
Italics: statistically significative.
a Median age of population.
from https://academic.oup.com/ejcts/article-abstract/37/5/1198/600918
Ospedaliera Careggi user
ary 2018seems to confirm the benefit of improved selection in a
category of patients with potential higher metastatic
disease.
Data suggest that even N1 disease is associated with a
relatively poor prognosis: so these patients should be
scheduled for surgery only after any effort has been made
to exclude lobar-node metastasis using more recent diag-
nostic tools (e.g., PET/CT and cytological confirmation by
endoscopic ultrasonography-guided fine-needle aspiration).
In case of doubt, a decision should be made on the basis of
operative risk and feasibility of radical anatomical resection
with acceptable residual pulmonary function.
It is reasonable to believe, although not demonstrated,
that determining the second tumour to be ametastasis would
change staging, prognosis and management. In 60% of our
patients, the pulmonary lesions presented an identical
histology. This result, in association with that of literature
[6,7,14,15,18,20], illustrates that synchronous MLCs can be
considered as metastasis in more than half of patients. We
made no attempt to differentiate between synchronous
MPLCs and intrapulmonary metastasis, because the criteria
of Martini and Melamed [22] are not easily applicable in the
clinical setting and no other clinical criteria to distinguish
them have been defined [13]. Although it is an important
biological question, from a practical point of view it may not
be relevant because our results, as those of other series,
showed no statistically different survival between patients
with multiple tumours of the same histology (which include
the subgroup with intrapulmonary metastasis) and patients
with multiple tumours of different histology (synchronous
MPLC) [4,6,7,14,15,18,20]. Probably, some patients withR.R. 95% CI p
0.667 0.207—2.144 0.496
3.050 0.327—28.477 0.328
1.959 0.188—20.412 0.574
0.597 0.225—1.584 0.300
1.048 0.389—2.823 0.926
0.519 0.185—1.454 0.212
0.603 0.195—1.862 0.379
0.496 0.186—1.327 0.163
0.202 0.075—0.546 0.002
4.221 1.742—10.410 0.001
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fore, these patients should undergo an extensive search for
mediastinal lymph node involvement and distant metastasis.
In addition to a CTscan of the chest, all these patients should
undergo a PETscan and brain CTor MRI to rule out metastatic
disease. Mediastinoscopy should also be performed routinely
to identify for surgery-only patients with no mediastinal
lymph node involvement.
In the absence of distant metastasis and lymph node
involvement, the question whether a patient had two
synchronous primary tumours or a primary tumour with an
isolated metastasis remains quite academic since it does not
imply different surgical approach, and long-term results
after surgery are comparable.
Other authors have recently reported good results in
patients who underwent resection of synchronous MLCs [4—
8,18,23], with 5-year survival rate ranging from 15% to 38%.
These results seem to be better than those in studies
published during the early 1990s and probably depend on a
more accurate selection of patients, thanks to recent
advances in the diagnostic tools.
Our study differs from many of these series since we have
included only patients whose lesions were identified
preoperatively. In the second period of our study (2000—
2007) patients showed a significantly better outcome than
those operated on in the first period (1990—1999) with a 5-
year survival rate of 43% and 16%, respectively. Since we did
not find any difference in the prognostic factors, complica-
tions and operative mortality between the two groups of
patients (data not shown), we can only speculate that these
improved results reflect a better selection process related to
PET-CT scan that was introduced and routinely used in these
patients after 2000. Although the incidence of node
metastasis before and after introduction of PET scan did
not significantly differ in surgically resected patients, it is
likely that the routine use of PET allowed us to select only
cases of minimal N2 disease and/or to exclude from surgery
patients with occult distant metastasis. Unfortunately, we
have no data on patients with node or distant metastasis
discovered preoperatively since these patients were not
candidates for surgery.
In patients with bilateral lesions, sequential delayed
resections are safer and can be performed with acceptable
morbidity andmortality. Our surgical mortality rate of 7% is in
line with that reported in recent studies ranging from 1.1% to
8.5% [6—8,18,23].
We did not find any difference in long-term survival when
we compared the group of patients who underwent
lobectomy or pneumonectomy with the group of patients
who underwent sublobar resection, although it could be
pointed out that lobar resections grants better long-term
results at the cost of slightly higher postoperative mortality.
Thus we believe that lobectomy should be performed in
presence of optimal respiratory reserve, although sublobar
resections are an acceptable alternative for patients with
resectable disease but marginal cardiopulmonary function
tests.
In preparation for the new TNM classification, incoming in
2009, the IASLC Staging Committee proposes to reclassify
ipsilateral nodules in a different lobe as T4 disease and
contralateral nodules as M1a disease. This assumption isrom https://academic.oup.com/ejcts/article-abstract/37/5/1198/600918
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nodules in a different lobe had a similar 5-year survival (22%)
to patients with T4 disease [24] and prognosis of patients with
contralateral nodules (5-year survival, 3%) was similar to
patients with pleural dissemination [25].
Although not significant, possibly because of small number
of patients, we also found a decrease in survival when the
additional nodule was located contralaterally than ipsilat-
erally to other lobe, with 5-year survival rate of 27% and 40%,
respectively. Other studies have reported contrasting results
with better survival in case of bilateral synchronous tumours
than in ipsilateral other lobe lesions [4—18]. This is possibly
related to selection bias, considering that patients with
bilateral tumours are selected more accurately, particularly
regarding to staging accuracy, as acknowledged by the
authors [18].
The limitations of this study are those inherent to all
retrospective studies, such as selection bias and conse-
quently lack of data regarding prognosis and survival of non-
surgically treated patients: no conclusion can be inferred
from the small percentage of patients who did not undergo
the second planned contralateral intervention.
5. Conclusions
Surgical resection of synchronous MLCs could be recom-
mendable after an extensive work-up (including PET scan
and mediastinoscopy routinely) to select node-negative
patients.
Provided there is no evidence of node and distant
metastasis, the hypothesis of synchronous MPLCs should
prevail on that of metastatic disease even in patients with a
second focus of the same type of cancer and surgery should
be performed in patients with adequate cardiopulmonary
reserve.
Results after surgery have improved in recent years,
probably due to better selection of patients.
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